TROV News Alert Trovagene Inc (TROV) 4.37 12/25/2014 03:47:2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Trovagene Inc (TROV) 4.37 $TROV

Trovagene Announces Presentation of Clinical Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Thu Dec 04, 8:05AM CST
Trovagene, Inc. (NASDAQ: TROV), today announced that clinical data will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place December 6-9, 2014 at the Moscone Center in San Francisco. The clinical data highlight the use of Trovagene's Precision Cancer MonitoringSM technology for the determination of mutational status and longitudinal monitoring of disease dynamics from both urine and plasma cell-free DNA, and will be presented by David Hyman, M.D., Memorial Sloan-Kettering Cancer Center.
TROV: 4.37 (+0.07)

Trovagene to Present at 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 26, 8:05AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference.
TROV: 4.37 (+0.07)

TrovaGene Cancer Technology Detects KRAS Mutation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 4:35PM CST
TrovaGene, Inc. (TROV) recently unveiled clinical study results that reflect the capability of its Precision Cancer Monitoring technology in detecting and monitoring KRAS mutation in circulating tumor DNA (ctDNA).
TROV: 4.37 (+0.07), ANIP: 55.24 (+1.79), AMAG: 43.02 (+0.90), AFFX: 9.80 (+0.05)

Trovagene Releases Clinical Study Results for the Detection and Monitoring of KRAS Mutations in Circulating Tumor DNA of Colorectal Cancer Patients
PR Newswire - Thu Nov 20, 8:08AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today clinical study results highlighting the Company's ability to detect and quantitate KRAS mutations in blood and urine samples from patients with advanced colorectal cancer. The data, generated using Trovagene's Precision Cancer Monitoring technology, show that quantitative changes of mutational signals in blood and urine are highly correlated and further establish the clinical applicability of a simple urine sample for cancer monitoring. The clinical study was conducted in collaboration with Genomac International, a cancer genomic research center based in Prague, Czech Republic. Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D., presented the study results at the EORTC-NCI-AACR International Symposium on Molecular Targets and Therapeutics Meeting in Barcelona, Spain.
TROV: 4.37 (+0.07)

Trovagene to Present at Upcoming Healthcare Conferences
PR Newswire - Wed Nov 12, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the following 2014 healthcare conferences: the Stifel 2014 Healthcare Conference and the Canaccord Genuity Medical Technologies and Diagnostics Forum. Each presentation will be webcast, and replays of each will be available at www.trovagene.com and archived for 90 days.
TROV: 4.37 (+0.07)

TrovaGene's (TROV) CEO Antonius Schuh on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:34PM CST

TROV: 4.37 (+0.07)

TrovaGene misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:04PM CST

TROV: 4.37 (+0.07)

Trovagene, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine months ended September 30, 2014.
TROV: 4.37 (+0.07)

What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:40PM CST
TrovaGene Inc. (TROV) is set to report third-quarter 2014 results on Nov 6.
MACK: 10.91 (+0.36), TROV: 4.37 (+0.07), PTCT: 51.66 (+0.76), HSIC: 137.87 (+0.15)

Trovagene Schedules Release of Third Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Wed Oct 29, 7:10AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the third quarter and the nine months ended September 30, 2014 on Thursday, November 6, 2014 at 4:00 p.m. Eastern Standard Time (1:00 p.m. Pacific Standard Time).
TROV: 4.37 (+0.07)

Clinical Study Using Trovagene's Precision Cancer Monitoring Platform Published in Cancer Discovery
PR Newswire - Mon Oct 27, 7:10AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, today announced the publication of clinical study results in a peer-reviewed journal, Cancer Discovery, featuring the Company's precision cancer monitoring technology and its ability to non-invasively determine oncogene mutation status and monitor response to BRAF inhibitor therapy in patients with histiocytic disease, a malignancy often associated with BRAF mutations. Study investigator Eli L. Diamond, M.D., a neuro-oncologist at Memorial Sloan Kettering Cancer Center, will present the clinical results at the 30th Annual Histiocyte Society Meeting on October 28 in Toronto, Canada.
TROV: 4.37 (+0.07)

Trovagene to Present at 13th Annual BIO Investor Forum
PR Newswire - Mon Oct 06, 3:30PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
TROV: 4.37 (+0.07)

Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium
PR Newswire - Wed Oct 01, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Eli Diamond, MD, Assistant Attending Neurologist at Memorial Sloan Kettering Cancer Center (MSK), presented clinical data from an ongoing study demonstrating the utility of Trovagene's precision cancer monitoring platform for the determination of oncogene mutational status in cell-free DNA obtained from a liquid biopsy. The results were presented to both treating physicians and patients at the ECD Global Alliance's Second International Medical Symposium, in collaboration with the National Institutes of Health (NIH), and expand upon clinical data presented earlier this year at the American Society of Clinical Oncology (ASCO) Annual Meeting.
TROV: 4.37 (+0.07)

Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Sep 17, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Bardelli was among the first to identify mutations in the kinase genes that are associated with colorectal cancer and other malignancies. Currently, he is at the Department of Oncology, Torino Medical School, Institute for Cancer Research in Candiolo, Italy.
TROV: 4.37 (+0.07)

Can The Uptrend Continue for TrovaGene (TROV)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:49AM CDT
Can The Uptrend Continue for TrovaGene (TROV)?
TROV: 4.37 (+0.07)

Increased Earnings Estimates Seen for TrovaGene (TROV): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:47AM CDT
TrovaGene has been witnessing a positive trend in its earnings estimate front and its share price has been increasing for past 4 weeks
TROV: 4.37 (+0.07)

How TrovaGene (TROV) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:36AM CDT
TrovaGene might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
TROV: 4.37 (+0.07)

TrovaGene (TROV) Jumps: Stock Rises 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:18AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as the company saw its shares rise over 9% on the day.
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), TROV: 4.37 (+0.07), GILD: 91.29 (+1.84)

Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics
PR Newswire - Tue Aug 26, 7:24AM CDT
Trovagene, Inc. (NASDAQ: TROV) presented data at the Next Generation Dx Summit; Moving Assays to the Clinic with an oral presentation entitled "Targeted Detection and Monitoring of Cell Free Tumor DNA in Urine." In this presentation Trovagene reported the analytical component of its Precision Cancer Monitoring (PCM) platform and results from several studies demonstrating high clinical sensitivity for the detection of tumor DNA mutations from urine samples of cancer patients. The PCM platform uses a proprietary urinary DNA extraction process and mutant tumor DNA enrichment methodologies coupled to next generation sequencing and proprietary bio-informatic analyses. The PCM platform enables translational studies for the demonstration of high clinical sensitivity, quantitative assessment of mutational copy levels and subsequent utility for urinary-based cell-free tumor DNA diagnostics.
TROV: 4.37 (+0.07)

Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.
PR Newswire - Mon Aug 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3). Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.
TROV: 4.37 (+0.07)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 10

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Antonio Filosa Takes the Helm as CEO of Stellantis N.V.

Updated Category News Views 335

Antonio Filosa Appointed as Stellantis N.V. Chief Executive Officer Stellantis N.V., a prominent player in the global automotive arena, has officially announced the appointment of Antonio Filosa as its new Chief Executive Officer. Filosa, who has amassed over 25 years of experience within the automotive sector, currently holds the position of Chief Operating Officer for...

Continue Reading
Understanding the Edwards Lifesciences Legal Landscape

Updated Category News Views 278

Understanding Recent Legal Issues for Investors In the world of investment, understanding legal implications can often feel overwhelming, especially when a company faces a class action lawsuit. Edwards Lifesciences Corporation, a name recognized for its innovative heart valve technologies, currently finds itself embroiled in legal battles that could shape its future and...

Continue Reading
Arrive Home and FormFree Join Forces to Enhance Homeownership Access

Updated Category News Views 155

Arrive Home Partners with FormFree for Innovative Solutions The innovative collaboration between Arrive Home and FormFree aims to transform the landscape of homeownership for many borrowers facing challenges due to limited credit histories. This partnership is particularly significant as it opens doors for those who have previously been overlooked by traditional credit...

Continue Reading
Verizon's $20 Billion Acquisition: A Strategic Expansion Ahead

Updated Category News Views 76

Verizon Announces Major Acquisition of Frontier Communications Verizon has recently made headlines by announcing a significant acquisition deal with Frontier Communications. This all-cash transaction, valued at $20 billion, underscores Verizon's dedication to substantially expanding its fiber network. Details of the Acquisition According to the proposed terms, Verizon...

Continue Reading
MoxiWorks Enhances Innovation Timeline with New Leadership and Funding

Updated Category News Views 174

MoxiWorks Enhances Innovation Timeline with New Leadership and Funding Funding from private equity and brokerage partners, along with new leadership, is set to transform MoxiWorks, a leading provider of sales and marketing software in the real estate sector. With substantial capital secured from its ownership group, which includes Vector Capital, Howard Hanna Real Estate...

Continue Reading